Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Tumor Suppressive Mir-7 Targeting PSME3 Improves the Efficacy of Histone Deacetylases Inhibitors in Multiple Myeloma

Masahiro Yamada, Sho Ikeda, Wataru Kuroki, Sayaka Iwama, Yuto Takahashi, Akihiro Kitadate, Fumito Abe, Hiroyuki Tagawa, Naoto Takahashi

Blood (2023) 142 (Supplement 1): 6592.

https://doi.org/10.1182/blood-2023-173475

Published: 2023

Journal Articles

Multiple Myeloma with 1q Gain/Amplification Shows Reduced CD38 Expression Via IL-6R Overexpression

Wataru Kuroki, Akihiro Kitadate, Masahiro Yamada, Sayaka Iwama, Yuto Takahashi, Yuki Fujioka, Takahiro Kobayashi, Sho Ikeda, Kentaro Narita, Kosei Matsue, Naoto Takahashi

Blood (2023) 142 (Supplement 1): 637.

https://doi.org/10.1182/blood-2023-173494

Published: 2023

Journal Articles

Hypoxia-Induced Oxidative Stress Promotes Proteasome Inhibitor Resistance Via Upregulation of Heme Oxygenase-1 in Multiple Myeloma

Ko Abe, Sho Ikeda, Miho Nara, Akihiro Kitadate, Hiroyuki Tagawa, Naoto Takahashi

Blood (2022) 140 (Supplement 1): 9974–9975.

https://doi.org/10.1182/blood-2022-159825

Published: 2022

Journal Articles

STAT3 Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma

Yuto Takahashi, Akihiro Kitadate, Sho Ikeda, Sayaka Iwama, Ko Abe, Hiroyuki Tagawa, Hideki Wakui, Naoto Takahashi

Blood (2022) 140 (Supplement 1): 5971–5972.

https://doi.org/10.1182/blood-2022-165113

Published: 2022

Journal Articles

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II

Toshiki Terao, MD, Yoichi Machida, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Kentaro Narita, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 1861.

https://doi.org/10.1182/blood-2019-130845

Published: 2019

Journal Articles

Clinical Features, Diagnosis, and Prognosis of 22 Cases of Neurolymphomatosis : A Single-Institution Experience over 12 Years

Kentaro Narita, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 1630.

https://doi.org/10.1182/blood-2019-126706

Published: 2019

Journal Articles

Hexokinase-2 Regulates Hypoxia-Inducible Autophagy, Leading to Enhance Anti-Apoptotic Capability of Refractory Multiple Myeloma

Sho Ikeda, MD PhD, Fumito Abe, MD PhD, Matsuda Yuka, Akihiro Kitadate, MD PhD, Takahiro Kobayashi, MD PhD, Naoto Takahashi, MD PhD, Hiroyuki Tagawa, MD PhD

Blood (2019) 134 (Supplement_1): 1787.

https://doi.org/10.1182/blood-2019-123360

Published: 2019

Journal Articles

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Akihiro Kitadate, MD PhD, Kentaro Narita, MD, Kota Fukumoto, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Youichi Machida, MD, Naoto Takahashi, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 2839.

https://doi.org/10.1182/blood-2019-122799

Published: 2019

Journal Articles

Prognostic Implications of Metabolic Total Volume and Total Lesion Glycolysis Assessed By PET/CT Combined with High Levels of Bone Marrow Plasma Cells Percentages As a Potential Risk Model in Patients with Newly Diagnosed Multiple Myeloma

Toshiki Terao, MD, Yoichi Machida, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Kentaro Narita, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 3193.

https://doi.org/10.1182/blood-2019-126784

Published: 2019

Journal Articles

Clinical and Prognostic Impact of (11;14)(q13;q32) Translocation on Patients with Multiple Myeloma

Daisuke Miura, MD, Kentaro Narita, MD, Ayumi Kuzume, MD, Rikako Tabata, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 5507.

https://doi.org/10.1182/blood-2019-130809

Published: 2019

Journal Articles

Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma

Kosei Matsue, Yoshiaki Abe, Akihiro Kitadate, Daisuke Miura, Kentaro Narita, Hiroki Kobayashi, Masami Takeuchi, Naoko Enzan, Atsushi Tanaka, Kengo Takeuchi

Blood (2019) 133 (11): 1257–1259.

https://doi.org/10.1182/blood-2018-11-887570

Published: 2019

Includes: Supplemental data

Journal Articles

Prevalence and Clinical Characteristics of False-Positive Aspergillus Galactomannan Test in Healthy Subjects and Patients with Hematologic Malignancies

Yoshiaki Abe, Kentaro Narita, MD, Hiroki Kobayashi, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 2408.

https://doi.org/10.1182/blood-2018-99-110939

Published: 2018

Journal Articles

Evaluation of the Revised International Staging System in 400 Patients with Symptomatic Myeloma in a Japanese Clinical Setting

Yoshiaki Abe, Yamashita Takeshi, Ueda Mikio, Kazutaka Sunami, MD PhD, Kentaro Narita, MD, Hiroki Kobayashi, MD, Hiroyuki Takamatsu, MD PhD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 4477.

https://doi.org/10.1182/blood-2018-99-109934

Published: 2018

Journal Articles

N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Is Associated with Both Left Ventricular Diastolic Dysfunction and Myeloma-Related Renal Insufficiency and Robustly Predicts Mortality in Patients with Symptomatic Multiple Myeloma

Yoshiaki Abe, Tetsuya Kobayashi, MD, Kentaro Narita, MD, Hiroki Kobayashi, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2018-99-110064

Published: 2018

Journal Articles

Diagnostic Significance of Hyperintense Lesion in the Pons on Brain Magnetic Resonance Imaging in Patients with Intravascular Lymphoma

Yoshiaki Abe, Kentaro Narita, MD, Hiroki Kobayashi, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 4214.

https://doi.org/10.1182/blood-2018-99-110946

Published: 2018

Journal Articles

Erythropoietin Level and Percentage of Urinary Albumin Are Important for Renal Recovery in Patients with Multiple Myeloma Receiving Novel Agents

Hiroki Kobayashi, MD, Yoshiaki Abe, Daisuke Miura, MD, Kentaro Narita, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 5571.

https://doi.org/10.1182/blood-2018-99-110495

Published: 2018

Journal Articles

Clinical Features and Predictive Factors of Early Mortality in Patients with MM Outside of Clinical Trials

Hiroki Kobayashi, MD, Yoshiaki Abe, Daisuke Miura, MD, Kentaro Narita, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2018-99-113750

Published: 2018

Journal Articles

Prognostic Value of Interim and End-of-Treatment PET-CT in Patients with Mature T-Cell and NK-Cell Lymphomas: A 10-Year Single Institution Study

Akihiro Kitadate, MD PhD, Kota Fukumoto, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, Kentaro Narita, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 2930.

https://doi.org/10.1182/blood-2018-99-113746

Published: 2018

Journal Articles

Prognostic Relevance of Medullary Abnormalities in the Appendicular Skeleton Detected By Positron Emission Tomography-Computed Tomography in Patients with Newly Diagnosed Multiple Myeloma

Yoshiaki Abe, Kentaro Narita, MD, Hiroki Kobayashi, MD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Toshihiro Ouchi, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 1878.

https://doi.org/10.1182/blood-2018-99-110062

Published: 2018

Journal Articles

CD38 Expression Levels on Myeloma Cells and the Frequency of Circulating CD38-Positive Treg Cells Are Associated with the Response to Daratumumab in Multiple Myeloma

Akihiro Kitadate, MD PhD, Hiroki Kobayashi, MD, Yoshiaki Abe, Kentaro Narita, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 1883.

https://doi.org/10.1182/blood-2018-99-113737

Published: 2018

NARROW

Tumor Suppressive Mir-7 Targeting PSME3 Improves the Efficacy of Histone Deacetylases Inhibitors in Multiple Myeloma

Multiple Myeloma with 1q Gain/Amplification Shows Reduced CD38 Expression Via IL-6R Overexpression

Hypoxia-Induced Oxidative Stress Promotes Proteasome Inhibitor Resistance Via Upregulation of Heme Oxygenase-1 in Multiple Myeloma

STAT3 Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II

Clinical Features, Diagnosis, and Prognosis of 22 Cases of Neurolymphomatosis : A Single-Institution Experience over 12 Years

Hexokinase-2 Regulates Hypoxia-Inducible Autophagy, Leading to Enhance Anti-Apoptotic Capability of Refractory Multiple Myeloma

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Prognostic Implications of Metabolic Total Volume and Total Lesion Glycolysis Assessed By PET/CT Combined with High Levels of Bone Marrow Plasma Cells Percentages As a Potential Risk Model in Patients with Newly Diagnosed Multiple Myeloma

Clinical and Prognostic Impact of (11;14)(q13;q32) Translocation on Patients with Multiple Myeloma

Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma

Prevalence and Clinical Characteristics of False-Positive Aspergillus Galactomannan Test in Healthy Subjects and Patients with Hematologic Malignancies

Evaluation of the Revised International Staging System in 400 Patients with Symptomatic Myeloma in a Japanese Clinical Setting

N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Is Associated with Both Left Ventricular Diastolic Dysfunction and Myeloma-Related Renal Insufficiency and Robustly Predicts Mortality in Patients with Symptomatic Multiple Myeloma

Diagnostic Significance of Hyperintense Lesion in the Pons on Brain Magnetic Resonance Imaging in Patients with Intravascular Lymphoma

Erythropoietin Level and Percentage of Urinary Albumin Are Important for Renal Recovery in Patients with Multiple Myeloma Receiving Novel Agents

Clinical Features and Predictive Factors of Early Mortality in Patients with MM Outside of Clinical Trials

Prognostic Value of Interim and End-of-Treatment PET-CT in Patients with Mature T-Cell and NK-Cell Lymphomas: A 10-Year Single Institution Study

Prognostic Relevance of Medullary Abnormalities in the Appendicular Skeleton Detected By Positron Emission Tomography-Computed Tomography in Patients with Newly Diagnosed Multiple Myeloma

CD38 Expression Levels on Myeloma Cells and the Frequency of Circulating CD38-Positive Treg Cells Are Associated with the Response to Daratumumab in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only